Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 1
2008 1
2009 1
2010 2
2011 2
2012 2
2013 1
2014 2
2015 3
2016 3
2017 2
2018 3
2019 6
2020 8
2021 11
2022 15
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Feb 19:S0161-6420(24)00134-9. doi: 10.1016/j.ophtha.2024.02.014. Online ahead of print. Ophthalmology. 2024. PMID: 38382813 Free article.
Anti-VEGF Treatment Strategies for 3 Subtypes of Neovascular Age-Related Macular Degeneration in a Clinical Setting: A Multicenter Cohort Study in Japan.
Yoneda K, Takeuchi M, Yasukawa T, Terasaki H, Yamamoto Y, Jujo T, Wakuta M, Matsubara H, Mitamura Y, Kato A, Kondo M, Kimura K, Takagi H, Gomi F, Sakamoto T; Japanese Clinical Retinal Study (J-CREST) Group. Yoneda K, et al. Among authors: matsubara h. Ophthalmol Retina. 2023 Oct;7(10):869-878. doi: 10.1016/j.oret.2023.06.002. Epub 2023 Jun 7. Ophthalmol Retina. 2023. PMID: 37295608
Visual prognosis of submacular hemorrhage secondary to age-related macular degeneration: A retrospective multicenter survey.
Inoue N, Kato A, Araki T, Kimura T, Kinoshita T, Okamoto F, Murakami T, Mitamura Y, Sakamoto T, Miki A, Takamura Y, Matsubara H, Tsujinaka H, Gomi F, Yasukawa T. Inoue N, et al. Among authors: matsubara h. PLoS One. 2022 Jul 21;17(7):e0271447. doi: 10.1371/journal.pone.0271447. eCollection 2022. PLoS One. 2022. PMID: 35862313 Free PMC article.
Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan.
Komori R, Takamura Y, Yamada Y, Morioka M, Matsubara H, Hirano T, Mitamura Y, Shimizu M, Kusuhara S, Murakami T, Nihei R, Ueda T, Kunikata H, Jujo T, Terasaki H, Nagasato D, Noda K, Osaka R, Nagai K, Yoshida S, Nozaki M, Noma H, Ishigooka G, Takahashi A, Sawada O, Kimura K, Inatani M. Komori R, et al. Among authors: matsubara h. J Clin Med. 2022 Nov 16;11(22):6794. doi: 10.3390/jcm11226794. J Clin Med. 2022. PMID: 36431271 Free PMC article.
69 results